Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Other Gross PP&E Adjustments (2016 - 2025)

Historic Other Gross PP&E Adjustments for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to -$20.3 million.

  • Ani Pharmaceuticals' Other Gross PP&E Adjustments rose 145.3% to -$20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$142.0 million, marking a year-over-year decrease of 4679.71%. This contributed to the annual value of $100.6 million for FY2024, which is 2973.64% up from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Other Gross PP&E Adjustments stood at -$20.3 million, which was up 145.3% from -$40.7 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Other Gross PP&E Adjustments' 5-year high stood at $100.6 million during Q4 2024, with a 5-year trough of -$60.3 million in Q1 2025.
  • For the 5-year period, Ani Pharmaceuticals' Other Gross PP&E Adjustments averaged around $20.4 million, with its median value being $32.1 million (2023).
  • Per our database at Business Quant, Ani Pharmaceuticals' Other Gross PP&E Adjustments soared by 3438.72% in 2022 and then crashed by 21799.06% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Other Gross PP&E Adjustments (Quarter) stood at $75.6 million in 2021, then rose by 0.44% to $76.0 million in 2022, then increased by 2.07% to $77.5 million in 2023, then increased by 29.74% to $100.6 million in 2024, then crashed by 120.23% to -$20.3 million in 2025.
  • Its Other Gross PP&E Adjustments stands at -$20.3 million for Q3 2025, versus -$40.7 million for Q2 2025 and -$60.3 million for Q1 2025.